一次情報の記録
Cullinanは、BCMAxCD3 T細胞エンゲージャーであるvelinotamigのPhase 1b/2a初期結果を難治性SLEで発表し、9例中8例の患者で臨床的改善、ベースライン蛋白尿を有する7例中4例で完全腎反応、自己抗体およびB細胞の深い低下、DLT、ICANSまたはGrade >=3 CRSのない良好な安全性プロファイルを示しました。これはSLEにおける本資産の初の臨床データ発表です。
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses Deep and sustained reduction in pathogenic autoantibodies and IgG reduction underscore potential in plasma-cell driven diseases Favorable safety profile in patients with refractory SLE CAMBRIDGE, Mass., Nov. 8, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-mo